{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vedotin&page=2", "query": { "condition": "Vedotin", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 251, "total_pages": 26, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vedotin&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vedotin&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T14:08:39.161Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02429375", "title": "Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hodgkin Lymphoma" ], "interventions": [ { "name": "Mocetinostat Plus Brentuximab Vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2015-04-22", "completion_date": "2021-02-17", "has_results": true, "last_update_posted_date": "2022-05-12", "last_synced_at": "2026-11-07T14:08:39.161Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02429375" }, { "nct_id": "NCT04491370", "title": "Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-cell Lymphoma", "Burkitt Lymphoma", "Diffuse Large B Cell Lymphoma", "Follicular Lymphoma", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Transformed Non-Hodgkin Lymphoma", "Richter Syndrome", "Hodgkin Lymphoma" ], "interventions": [ { "name": "Polatuzumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New York Medical College", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "12 Years to 70 Years" }, "enrollment_count": 20, "start_date": "2021-08-01", "completion_date": "2027-08-15", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-11-07T14:08:39.161Z", "location_count": 1, "location_summary": "Valhalla, New York", "locations": [ { "city": "Valhalla", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04491370" }, { "nct_id": "NCT05923190", "title": "Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma", "Metastatic Urothelial Carcinoma", "Locally Advanced Urothelial Carcinoma" ], "interventions": [ { "name": "Enfortumab vedotin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2023-06-14", "completion_date": "2029-07-01", "has_results": false, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-11-07T14:08:39.161Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05923190" }, { "nct_id": "NCT02363283", "title": "Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Uveal Melanoma", "Stage IV Uveal Melanoma AJCC v7" ], "interventions": [ { "name": "Glembatumumab Vedotin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2015-09-16", "completion_date": "2018-07-02", "has_results": true, "last_update_posted_date": "2020-08-21", "last_synced_at": "2026-11-07T14:08:39.161Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02363283" }, { "nct_id": "NCT03485209", "title": "Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Exocrine Pancreatic Cancer", "Carcinoma, Squamous Cell of Head and Neck" ], "interventions": [ { "name": "tisotumab vedotin", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 350, "start_date": "2018-06-25", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-11-07T14:08:39.161Z", "location_count": 124, "location_summary": "Encinitas, California • La Jolla, California • Sacramento, California + 57 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03485209" }, { "nct_id": "NCT02091999", "title": "A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Urothelial Cancer and Other Malignant Solid Tumors" ], "interventions": [ { "name": "enfortumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 213, "start_date": "2014-05-14", "completion_date": "2022-12-07", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-11-07T14:08:39.161Z", "location_count": 18, "location_summary": "Los Angeles, California • Stanford, California • Aurora, Colorado + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02091999" }, { "nct_id": "NCT01100502", "title": "A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Disease, Hodgkin" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 329, "start_date": "2010-04-30", "completion_date": "2020-04-27", "has_results": true, "last_update_posted_date": "2021-05-14", "last_synced_at": "2026-11-07T14:08:39.161Z", "location_count": 32, "location_summary": "Duarte, California • San Francisco, California • Stanford, California + 26 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01100502" }, { "nct_id": "NCT07815665", "title": "A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Metastatic Urothelial Carcinoma", "Metastatic Urothelial Carcinoma (UC)" ], "interventions": [ { "name": "Ivonescimab Dose 1", "type": "DRUG" }, { "name": "enfortumab vedotin (EV)", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Ivonescimab Dose 2", "type": "DRUG" }, { "name": "Ivonescimab RP3D", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Summit Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 800, "start_date": "2026-09-10", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-11-07T14:08:39.161Z", "location_count": 7, "location_summary": "Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 4 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07815665" }, { "nct_id": "NCT04389632", "title": "A Study of Sigvotatug Vedotin in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small Cell Lung", "Squamous Cell Carcinoma of Head and Neck", "HER2 Negative Breast Neoplasms", "Esophageal Squamous Cell Carcinoma", "Esophageal Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Ovarian Neoplasms", "Cutaneous Squamous Cell Cancer", "Exocrine Pancreatic Adenocarcinoma", "Urinary Bladder Neoplasms", "Uterine Cervical Neoplasms", "Stomach Neoplasms" ], "interventions": [ { "name": "sigvotatug vedotin", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1006, "start_date": "2020-06-08", "completion_date": "2029-03-22", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-11-07T14:08:39.161Z", "location_count": 106, "location_summary": "Anchorage, Alaska • Fayetteville, Arkansas • Rogers, Arkansas + 61 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04389632" }, { "nct_id": "NCT07529808", "title": "Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric Cancer", "Gastric Adenocarcinoma", "Gastric (Stomach) Cancer", "Gastroesophageal Adenocarcinoma", "Gastroesophageal Cancer (GC)", "Gastroesophageal Junction (GEJ) Adenocarcinoma", "Gastroesophageal Junction (GEJ) Cancer", "Gastrointestinal Cancer Metastatic", "Gastrointestinal Adenocarcinoma", "Gastrointestinal Cancers", "Colorectal (Colon or Rectal) Cancer", "Pancreatic Cancer", "CDH17-positive Advanced Solid Tumors", "Advanced Gastric Cancer" ], "interventions": [ { "name": "BHB810", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BigHat Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 164, "start_date": "2026-07-16", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-11-07T14:08:39.161Z", "location_count": 3, "location_summary": "Duarte, California • Santa Monica, California • Fairfax, Virginia", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07529808" } ] }